DRUG
Octreotide subcutaneous depot
Commercially available octreotide subcutaneous depot treatment administered by participants for a maximum duration up to 2 years in the study
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
Status
Recruiting
Phase
Not applicable
Enrollment
200
Locations
5
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
May 13, 2026
Study start
Jun 5, 2026
Primary completion
Jun 2029
Study completion
Jun 2029
Results posted
Not reported
Registry updated
Jun 30, 2026
Outcomes
What the study measures.
Primary outcomes
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
Time frame · From enrollment to the end of treatment at 2 years
Secondary outcomes
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
Time frame · From enrollment to the end of treatment at 2 years
Change in proportion of participants with IGF-1 ≤1×ULN over time.
Time frame · From enrollment to the end of treatment at 2 years
Change in GH levels over time.
Time frame · From enrollment to the end of treatment at 2 years
Change in proportion of participants with GH levels <1.0 μg/L over time.
Time frame · From enrollment to the end of treatment at 2 years
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
Time frame · From enrollment to the end of treatment at 2 years
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms.
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
Time frame · From enrollment to the end of treatment at 2 years
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life.
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
Time frame · From enrollment to the end of treatment at 2 years
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction.
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
Time frame · From enrollment to the end of treatment at 2 years
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms.
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
Time frame · From enrollment to the end of treatment at 2 years
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for acromegaly Exclusion Criteria: * Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly * Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
Study locations
5 registered sites.
Germany. Showing up to 24 locations stored in the fast local snapshot.
Universitaetsklinikum Aachen
Aachen, Germany
Universitaetsklinikum Leipzig
Leipzig, Germany
Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
Magdeburg, Germany
Medicover Neuroendokrinologie MVZ
München, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Octreotide.
NCT IDStudyPhase / statusEnrollmentUpdated
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI) · Colorectal Neuroendocrine Tumor G1 · Gastric Neuroendocrine Tumor G1
Phase 3
Active, not recruiting
427
2026-07
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Camurus AB · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
332
2026-07
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA · Acromegaly
Phase 3
Recruiting
119
2026-07
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · ACTH · Cushing's Syndrome
Phase 2
Recruiting
80
2026-07
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
M.D. Anderson Cancer Center · Neuroendocrine Carcinoma · Islet Cell Carcinoma
Phase 2
Completed
67
2026-07
Effect of Insulin Lowering on Lipogenesis
Columbia University · Hyperinsulinemia · Insulin Resistance
Phase 1
Recruiting
25
2026-07
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
Triastek (Shanghai) Limited · Acromegaly
Phase 1
Not yet recruiting
18
2026-06
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 3
Recruiting
141
2026-06
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.